Hormonal
Resmetirom (80-100 mg daily) is the first FDA-approved pharmacotherapy for MASH with fibrosis, demonstrating significant improvement in liver fibrosis and MASH resolution compared to placebo.
Resmetirom is the first approved drug for MASH with fibrosis. It works by targeting thyroid hormone receptors in the liver to reduce fat and inflammation. Take 80mg or 100mg daily. Expect possible mild stomach issues, but the drug has proven to improve liver scarring in clinical trials.
Resmetirom resulted in a significant reduction in hepatic fat after 12 weeks or 36 weeks in patients with MASH in a phase 2 clinical trial... The results showed that both 80 mg and 100 mg of resmetirom were superior to placebo in alleviating MASH and improving liver fibrosis by at least one stage... Resmetirom treatment reduced low-density lipoprotein cholesterol and triglycerides... These results have made resmetirom the world’s first approved drug for MASH.
Why this rating
Supported by Phase 2 and Phase 3 randomized controlled trials showing statistically significant histological improvements.
Source
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Da Zhou et al. · Chinese Medical Journal · 2024
DOI 10.1097/cm9.0000000000003355
More from this paper
- GLP-1 receptor agonists (e.g., semaglutide, liraglutide) improve MASH resolution but do not significantly improve liver fibrosis in patients with compensated cirrhosis.Good
- Pioglitazone (30-45 mg) improves hepatic steatosis and inflammation in MASH patients, particularly those with type 2 diabetes, but carries risks of weight gain and bone fractures.Good
- Tirzepatide (10-15 mg weekly) is more effective than placebo in resolving MASH without worsening fibrosis, showing substantial weight loss and metabolic improvements.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →